Drug intelligence / Profile preview

ACE-EXTRA

Development stage
Unknown
Lead developer
Yogi Group
Modality
Small Molecules
Administration
Oral
01

Overview

ACE-EXTRA is an oral fixed-dose combination medication developed and manufactured by Yogi Care Pharmaceutical Pvt Ltd. It contains 100 mg of aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), and 500 mg of paracetamol (acetaminophen), an analgesic and antipyretic. Aceclofenac works by inhibiting the cyclooxygenase (COX) enzymes, thereby reducing the synthesis of inflammatory prostaglandins, while paracetamol provides additional pain relief and fever reduction through central mechanisms. Despite the 'ACE' prefix in its name, the drug is not an angiotensin-converting enzyme (ACE) inhibitor and is not used to treat hypertension or cardiovascular disease; the name is derived from aceclofenac. It is primarily indicated for the management of acute pain, fever, and inflammatory conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.

Brand names
ACE-EXTRA
Other names
aceclofenac + paracetamol
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on ACE-EXTRA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACE-EXTRA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call